Benitec Biopharma (BNTC) Research & Development (2019 - 2025)
Benitec Biopharma (BNTC) posted Research & Development of $5.8 million for Q4 2025, up 73.12% sequentially from $3.4 million in Q3 2025, and up 8.34% YoY from $5.4 million in Q4 2024.
Benitec Biopharma (BNTC) Research & Development (2019 - 2025) Analysis & Trends
Benitec Biopharma has reported Research & Development for 7 years, with the latest figure at $5.8 million in Q4 2025.
- Quarterly Research & Development rose 8.34% year-over-year to $5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.6 million (up 23.38% YoY) and the FY2025 annual result came in at $18.3 million, up 17.45% from the prior year.
- Research & Development grew to $5.8 million in Q4 2025 per BNTC's latest filing, from $3.4 million in the prior quarter.
- Over five years, Research & Development peaked at $6.5 million in Q1 2025 and troughed at $2.2 million in Q1 2022.
- A 5-year average of $3.6 million and a median of $3.2 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2021 and 2022: Research & Development soared 259.17% in 2021, then slipped 21.28% in 2022.
- Over 5 years, Research & Development stood at $3.1 million in 2021, then gained by 19.55% to $3.8 million in 2022, then jumped by 35.66% to $5.1 million in 2023, then advanced by 5.55% to $5.4 million in 2024, then increased by 8.34% to $5.8 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $5.8 million, $3.4 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Benitec Biopharma | 577.39 Mn | 388.49 Mn | - | 5.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.83 Mn |
| Sep 30, 2025 | 3.37 Mn |
| Jun 30, 2025 | 2.87 Mn |
| Mar 31, 2025 | 6.50 Mn |
| Dec 31, 2024 | 5.39 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 3.51 Mn |
| Mar 31, 2024 | 2.57 Mn |
| Dec 31, 2023 | 5.10 Mn |
| Sep 30, 2023 | 4.43 Mn |
| Jun 30, 2023 | 3.19 Mn |
| Mar 31, 2023 | 3.17 Mn |
| Dec 31, 2022 | 3.76 Mn |
| Sep 30, 2022 | 2.66 Mn |
| Jun 30, 2022 | 3.18 Mn |
| Mar 31, 2022 | 2.17 Mn |
| Dec 31, 2021 | 3.15 Mn |
| Sep 30, 2021 | 2.78 Mn |
| Jun 30, 2021 | 2.32 Mn |
| Mar 31, 2021 | 2.76 Mn |